stockrow
Saturday 7 November 2026
Export KLRA’s income statement to Excel — free account
Kailera Therapeutics, Inc.
KLRA Healthcare Biotechnology
- EPS
- +100.0%
- Free cash flow
- −326.0%
Quarter to September 2026, against a year earlier
12.97
0.80
+6.57%
Follow KLRA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
0.00% | 0.00% | 0.00% | (85.74%) | |
| 0.00% | (52.25%) | (48.24%) | (55.25%) | ||
ROIC |
(110.14%) | (338.40%) | (97.06%) | (182.92%) | |
Return on Tangible Assets |
(29.03%) | (43.96%) | (34.49%) | (39.60%) | |
Free Cash Flow per Share |
(601,050.00) | (7,885.14) | (2.17) | (2.51) | |
Free Cash Flow |
(120.21) | (170.32) | (221.61) | (325.58) | |
| Other line items | |||||
Cash ROIC |
(10.17%) | (15.78%) | (10.89%) | (16.85%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.81 | 0.81 | 0.76 | 0.93 | |
Depreciation/Fixed assets |
0.16 | 0.19 | 0.22 | 0.26 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(601,050.00) | (7,885.14) | (2.17) | (2.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026